The DOI matches its Crossref record; 269 of the 269 references it cites were found in a registry or an index.
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Open accessAbstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, characterized by raised blood glucose levels and impaired lipid metabolism resulting from insulin resistance and relative insulin deficiency. In diabetes, the peculiar plasma lipoprotein phenotype, consisting in higher levels of apolipoprotein B-containing lipoproteins, hypertriglyceridemia, low levels of HDL cholesterol, elevated number of small, dense LDL, and increased non-HDL cholesterol, results from an increased synthesis and impaired clearance of triglyceride rich lipoproteins. This condition accelerates the development of the atherosclerotic cardiovascular disease (ASCVD), the most common cause of death in T2DM patients. Here, we review the alteration of structure, functions, and distribution of circulating lipoproteins and the pathophysiological mechanisms that induce these modifications in T2DM. The review analyzes the influence of diabetes-associated metabolic imbalances throughout the entire process of the atherosclerotic plaque formation, from lipoprotein synthesis to potential plaque destabilization. Addressing the different pathophysiological mechanisms, we suggest improved approaches for assessing the risk of adverse cardiovascular events and clinical strategies to reduce cardiovascular risk in T2DM and cardiometabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in metabolic disorders such as insulin resistance, type 2 diabetes, chronic kidney disease, and nephrotic syndrome, an imbalance between production and clearance of TRLs favors their accumulation, promoting a lipid profile characterized by elevated TG, increased remnant particles, and changes in lipoprotein composition often associated with atherogenic risk [12, 13].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Vascular smooth muscle cells in atherosclerosis
Bennett, M. R., Sinha, S., & Owens, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306361 · Cited by 2,179
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
SCORE2 working group and ESC Cardiovascular risk collaboration, Hageman, S., Pennells, L., Ojeda, F., Kaptoge, S., Kuulasmaa, K., de Vries, T., Xu, Z., Kee, F., Chung, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab309 · Cited by 1,810
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Cited by
Sorted by citations
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
“Athero-genic dyslipidaemia, inflammatory cytokines, ROS and immune cells are also involved in formation of atheromatous plaques 132–135 .”
Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk
Berisha, H., Hattab, R., Comi, L., Giglione, C., Migliaccio, S., & Magni, P. (2025) · Nutrients · doi:10.3390/nu17050776 · Cited by 85
“…TG and reduced HDL-C levels, which are hallmark features of metabolic syndrome and associated with increased cardiovascular risk [32]. characterized by elevated TG and reduced HDL-C levels, which are hallmark features of metabolic syndrome and associated with increased cardiovascular risk [32].”
The link between diabetes and cardiovascular disease
Borén, J., Öörni, K., & Catapano, A. L. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117607 · Cited by 44
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · PubMed · Cited by 29
Zhang, Z., & Tan, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1515559 · Cited by 25
Metadata
- Authors
- Luciani, L., Pedrelli, M., & Parini, P.
- Affiliations
- Scuola Superiore Sant'Anna (IT)
- Karolinska University Hospital (SE)
- Corresponding author
- Parini, Paolo
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 394
- Pages
- 117545
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4394875384
- Cited by
- 72
- References
- 268
- Citations by year
- 2026: 30 · 2025: 32 · 2024: 9
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Atherosclerosis (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission
- Karolinska Institutet
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- type 2 diabetes, atherogenesis, lipoprotein metabolism, atherosclerotic cardiovascular disease, apolipoprotein B, small dense LDL, hypertriglyceridemia, HDL cholesterol, triglyceride-rich lipoproteins, insulin resistance, atherosclerotic plaque formation, plaque destabilization, cardiovascular risk assessment, cardiometabolic disease
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Lipoproteins, Biomarkers, Dyslipidemias, Atherosclerosis, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
